Short answer
LivaNova PLC (LIVN) filed its Q1 2026 10-Q quarterly report on May 6, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $362M (up 14.3% year over year) with net income of $22M.
Q1 2026 key financials · XBRL
- Revenue
- $362M
- +14.3% YoY
- Net income
- $22M
- +106.8% YoY
- Operating margin
- 11.4%
- Gross margin
- 67.3%
- EPS (diluted)
- $0.40
- +106.7% YoY
Source: XBRL data from the LivaNova PLC (LIVN) Q1 2026 10-Q on SEC EDGAR. USD.
LivaNova PLC Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $362.3M, up 14.3% YoY from $316.9M
- Operating margin 11.4% vs 15.3% YoY; net income $22.3M vs $327.3M loss
- Best segment Cardiopulmonary: revenue $208.7M, up 18.3%; segment income $30.1M vs $24.7M
- Worst segment Neuromodulation: segment income $44.2M, down 15.7% from $52.4M
- Cash $539.7M vs $635.6M; operating cash flow $15.2M vs $24.0M; $95.9M debt repayment reducing financing cash flow by $94.2M
Risk Factors
- Iran sanctions risk: $1.6 million revenue and $0.8 million net profit from Iranian activities
- Compliance risk: Limited visibility into Iranian distributors’ customers and potential government-owned entities
- Regulatory uncertainty: Evolving U.S., UK, European Union, and other sanctions laws
- Business continuity risk: Company intends to continue Iran operations despite sanctions complexity
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other LivaNova PLC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.